{"podcast":{"title":"Let's Talk Risk! Podcast","slug":"let-s-talk-risk-podcast-6693844","podcast_index_feed_id":6693844,"rss_url":"https://api.substack.com/feed/podcast/1477050.rss","website_url":"https://naveenagarwalphd.substack.com/podcast","image_url":"https://substackcdn.com/feed/podcast/1477050/ee2039dcd34796f25b1263b7e1659bef.jpg","author":"Where MedTech professionals gain clarity and confidence to navigate complex decisions.","episode_count":182,"summary":"Where MedTech professionals gain clarity and confidence to navigate complex risk, quality, and leadership challenges.","last_synced_at":"2026-09-12T00:18:22.009520+00:00","page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844"},"episode":{"title":"Deep Dive: The PFAS Substitution Risk Paradox in Medical Devices","slug":"deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices","published_at":"2026-09-04T12:00:00+00:00","page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices","show_page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844","url":"https://naveenagarwalphd.substack.com/p/deep-dive-the-pfas-substitution-risk-paradox","audio_url":"https://api.substack.com/feed/podcast/214090831/8702c185e17deea0f3659ae99e493eed.mp3","summary":"FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices. What happens when pressure to eliminate a material creates greater risk for the patient? This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers , and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category. Key highlights covered in the audio: * Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices. * FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE. * Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety. * This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications. * The decision belongs inside risk management. Under ISO 14971 , the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed. * A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material. Keywords: PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management 🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived…","meta_description":"FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices. What happens when pressure to eliminate a material creates gre…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1226,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}